{"id":"ki1106-4g-qd","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Anemia"},{"rate":"5-10%","effect":"Thrombocytopenia"},{"rate":"5-10%","effect":"Neutropenia"},{"rate":"5-10%","effect":"Leukopenia"},{"rate":"5-10%","effect":"Anorexia"},{"rate":"5-10%","effect":"Weight loss"}]},"_chembl":{"chemblId":"CHEMBL5812782","moleculeType":null,"molecularWeight":"576.07"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"KI1106 works by blocking the interaction between CD47 and SIRPα, which is involved in immune evasion by cancer cells. This blockade leads to the activation of macrophages and enhanced anti-tumor immune responses.","oneSentence":"KI1106 is a small molecule targeting the CD47/SIRPα axis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:17:52.468Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory multiple myeloma"}]},"trialDetails":[{"nctId":"NCT03482180","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of KI1106 in Patients Whose TG Level is Not Adequately Controlled With Atorvastatin Calcium Monotherapy While LDL-C is Properly Controlled","status":"COMPLETED","sponsor":"Kuhnil Pharmaceutical Co., Ltd.","startDate":"2016-05-04","conditions":"Dyslipidemias","enrollment":215}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"KI1106 4g, QD","genericName":"KI1106 4g, QD","companyName":"Kuhnil Pharmaceutical Co., Ltd.","companyId":"kuhnil-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"KI1106 is a small molecule targeting the CD47/SIRPα axis. Used for Relapsed or refractory multiple myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}